SRT501, a SIRT1 activator, is our proprietary formulation of resveratrol with improved bioavailability.

SRT501 was found to be safe and well tolerated in two Phase IIa clinical studies in patients with Type 2 Diabetes.  In the second Phase IIa trial, Type 2 Diabetic patients were given 1.25 or 2.5 grams of SRT501 orally twice daily for 28 days. The patient group receiving 2.5 grams twice a day had significantly lower blood glucose levels as determined through an oral glucose tolerance test on day 28 at the test’s two-hour time point, as compared to the placebo group. 

At 2.5 grams twice daily, the study also found that SRT501 had a statistically significant lowering of both fasting blood glucose and glucose levels after meals, known as the postprandial period, an important timeframe for patients with Type 2 Diabetes who need better control of blood sugar levels after eating.

SRT501 is currently being tested in patients with Type 2 Diabetes in a Phase IIa study in combination with metformin, the current front-line therapy for Type 2 Diabetes. Results from this trial are expected in the first half of 2009.

The company is also under way with a Phase IIa cancer trial with SRT501.